CORE LAB REPORTS SECOND QUARTER 2024 RESULTS
Core Laboratories Inc. (NYSE: CLB) reported Q2 2024 revenue of $130.6 million, up slightly sequentially and year-over-year. Operating income was $16.0 million, or $16.4 million ex-items, up 10% sequentially and 5% year-over-year. GAAP EPS was $0.19, or $0.22 ex-items, up 16% sequentially and 5% year-over-year. Free cash flow improved to $14.3 million, and net debt was reduced by $15.8 million.
Reservoir Description revenue grew 2% sequentially to $86.3 million, while Production Enhancement revenue slightly decreased to $44.3 million. The company maintains a constructive outlook on international upstream projects for 2024 and anticipates sustainable client activity growth in the years ahead.
Core Laboratories Inc. (NYSE: CLB) ha riportato un fatturato nel Q2 2024 di 130,6 milioni di dollari, in aumento leggermente rispetto al trimestre precedente e rispetto all'anno precedente. Il reddito operativo è stato di 16,0 milioni di dollari, o 16,4 milioni al netto degli elementi straordinari, in crescita del 10% rispetto al trimestre precedente e del 5% anno su anno. L'EPS GAAP è stato di 0,19 dollari, o 0,22 dollari al netto degli elementi straordinari, in aumento del 16% rispetto al trimestre precedente e del 5% anno su anno. Il flusso di cassa libero è migliorato a 14,3 milioni di dollari e il debito netto è stato ridotto di 15,8 milioni di dollari.
Il fatturato della Descrizione del Bacino è cresciuto del 2% rispetto al trimestre precedente, raggiungendo 86,3 milioni di dollari, mentre il fatturato per il Miglioramento della Produzione è leggermente diminuito a 44,3 milioni di dollari. L'azienda mantiene un outlook ottimista sui progetti internazionali di esplorazione per il 2024 e prevede una crescita sostenibile dell'attività dei clienti negli anni a venire.
Core Laboratories Inc. (NYSE: CLB) reportó ingresos de 130.6 millones de dólares en el Q2 2024, con un ligero aumento en comparación con el trimestre anterior y el año pasado. El ingreso operativo fue de 16.0 millones de dólares, o 16.4 millones excluyendo elementos extraordinarios, lo que representa un crecimiento del 10% en comparación con el trimestre anterior y del 5% en comparación con el año anterior. El EPS GAAP fue de 0.19 dólares, o 0.22 dólares excluyendo elementos extraordinarios, con un aumento del 16% en comparación con el trimestre anterior y del 5% en comparación con el año anterior. El flujo de caja libre mejoró a 14.3 millones de dólares y la deuda neta se redujo en 15.8 millones de dólares.
Los ingresos por Descripción de Reservorios crecieron un 2% en comparación con el trimestre anterior, alcanzando los 86.3 millones de dólares, mientras que los ingresos por Mejora de Producción disminuyeron ligeramente a 44.3 millones de dólares. La empresa mantiene una perspectiva constructiva sobre los proyectos internacionales de upstream para 2024 y anticipa un crecimiento sostenible de la actividad del cliente en los próximos años.
Core Laboratories Inc. (NYSE: CLB)는 2024년 2분기 매출이 1억 3천 6백만 달러로, 이전 분기 및 작년 대비 약간 증가했다고 보고했습니다. 운영 수익은 1,600만 달러였으며, 비정기 항목 제외 시 1,640만 달러로, 이전 분기 대비 10%, 전년 대비 5% 증가했습니다. GAAP 기준 주당 순이익(EPS)은 0.19달러, 비정기 항목 제외 시 0.22달러로, 이전 분기 대비 16%, 전년 대비 5% 증가했습니다. 자유 현금 흐름은 1,430만 달러로 개선되었고, 순부채는 1,580만 달러 감소했습니다.
저수지 설명 매출은 이전 분기 대비 2% 증가하여 8,630만 달러에 도달했으며, 생산 개선 매출은 약간 감소하여 4,430만 달러에 이르렀습니다. 회사는 2024년 국제 업스트림 프로젝트에 대해 긍정적인 전망을 유지하고 있으며, 향후 몇 년 동안 지속적인 고객 활동 성장을 예상하고 있습니다.
Core Laboratories Inc. (NYSE: CLB) a rapporté un chiffre d'affaires au T2 2024 de 130,6 millions de dollars, en légère hausse par rapport au trimestre précédent et à l'année précédente. Le revenu opérationnel était de 16,0 millions de dollars, ou 16,4 millions de dollars hors éléments exceptionnels, soit une augmentation de 10% par rapport au trimestre précédent et de 5% par rapport à l'année précédente. Le BPA GAAP était de 0,19 dollar, ou 0,22 dollar hors éléments exceptionnels, en hausse de 16% par rapport au trimestre précédent et de 5% par rapport à l'année précédente. Le flux de trésorerie libre a augmenté pour atteindre 14,3 millions de dollars, et la dette nette a été réduite de 15,8 millions de dollars.
Les revenus de la description des réservoirs ont augmenté de 2% par rapport au trimestre précédent, atteignant 86,3 millions de dollars, tandis que les revenus de l'amélioration de la production ont légèrement diminué à 44,3 millions de dollars. L'entreprise maintient une perspective constructive sur les projets internationaux en amont pour 2024 et anticipe une croissance soutenue de l'activité des clients dans les années à venir.
Core Laboratories Inc. (NYSE: CLB) berichtete von einem Umsatz im Q2 2024 von 130,6 Millionen Dollar, was einen leichten Anstieg im Vergleich zum vorherigen Quartal und zum Vorjahr darstellt. Das Betriebsergebnis betrug 16,0 Millionen Dollar, oder 16,4 Millionen Dollar ohne Einmaleffekte, was einem Anstieg von 10% im Vergleich zum vorherigen Quartal und 5% im Vergleich zum Vorjahr entspricht. GAAP EPS betrug 0,19 Dollar, oder 0,22 Dollar ohne Einmaleffekte, was einen Anstieg von 16% im Vergleich zum vorherigen Quartal und 5% im Vergleich zum Vorjahr bedeutet. Der freie Cashflow verbesserte sich auf 14,3 Millionen Dollar, und die Nettoverbindlichkeiten wurden um 15,8 Millionen Dollar reduziert.
Die Einnahmen aus Reservoirbeschreibung stiegen um 2% im Vergleich zum vorherigen Quartal auf 86,3 Millionen Dollar, während die Einnahmen aus Produktionsverbesserungen leicht auf 44,3 Millionen Dollar zurückgingen. Das Unternehmen hält eine optimistische Einschätzung für internationale Upstream-Projekte im Jahr 2024 aufrecht und erwartet ein nachhaltiges Wachstum der Kundenaktivitäten in den kommenden Jahren.
- Revenue increased slightly year-over-year to $130.6 million
- Operating income ex-items up 10% sequentially to $16.4 million
- EPS ex-items increased 16% sequentially to $0.22
- Free cash flow improved to $14.3 million
- Net debt reduced by $15.8 million
- Leverage ratio improved from 1.76 to 1.66, lowest in over five years
- Reservoir Description revenue grew 2% sequentially to $86.3 million
- Production Enhancement revenue slightly decreased sequentially
- U.S. onshore client activity expected to be sequentially lower in Q3
- Demand for laboratory assay work negatively impacted by geopolitical events
- U.S. frac spread count continues to trend lower
Insights
Core Laboratories' Q2 2024 results demonstrate modest growth and operational improvements, despite challenging market conditions. The company reported
Key financial highlights include:
- EPS (ex-items) of
$0.22 , up16% sequentially and5% year-over-year - Operating margins (ex-items) of
13% , expanding over 100 basis points sequentially - Free cash flow of
$14.3 million - Net debt reduced by
$15.8 million
The company's focus on debt reduction is evident, with the leverage ratio improving from 1.76 to 1.66, the lowest in over five years. This financial discipline, combined with positive free cash flow generation, positions Core Labs well for future growth.
However, investors should note potential headwinds, including geopolitical disruptions affecting the Reservoir Description segment and softening completion activity in the U.S. impacting the Production Enhancement segment. The company's guidance for Q3 2024 suggests cautious optimism, with projected revenue of
Core Laboratories' Q2 results reflect the complex dynamics of the global oil and gas industry. The Reservoir Description segment, which derives
The Production Enhancement segment, however, faced challenges with slightly lower revenue, primarily due to reduced international product sales. This was partially offset by strong growth in the U.S. market, highlighting the segment's ability to adapt to shifting market conditions.
Core Labs' engagement in key projects, such as the natural gas discoveries offshore North Sumatra and the emulsion problem analysis for a Middle Eastern NOC, demonstrates the company's technical expertise and its critical role in optimizing reservoir performance. These projects not only provide immediate revenue but also strengthen Core Labs' position as a leading provider of reservoir description services.
Looking ahead, the company's outlook aligns with industry projections of growing crude oil demand. However, near-term volatility due to economic and geopolitical risks could impact project timelines and investment decisions. The anticipated growth in international upstream projects, particularly in the Middle East, South Atlantic Margin and parts of Asia Pacific and West Africa, presents opportunities for Core Labs to leverage its specialized services and technologies.
Core Laboratories' Q2 2024 results offer valuable insights into the broader oil and gas industry trends. The company's performance reflects a cautious but optimistic outlook for the sector, with particular strength in international markets.
Key market observations:
- International and offshore activity levels are driving growth, particularly in the Reservoir Description segment.
- U.S. onshore activity shows signs of softening, which could impact the Production Enhancement segment in the coming quarters.
- The industry faces ongoing challenges from geopolitical conflicts and natural disasters, as evidenced by the impact on laboratory assay work in Q3.
Core Labs' projections align with forecasts from major energy agencies (IEA, EIA and OPEC) that predict crude oil demand growth of 1-2 million barrels per day for both 2024 and 2025. This outlook supports the need for continued investment in both onshore and offshore field development.
The company's focus on technology investments and growth opportunities positions it well to capitalize on the anticipated multi-year cycle of expanded client project activity, particularly in the Middle East. However, investors should monitor potential risks, including volatile crude oil markets due to global economic uncertainties and geopolitical tensions.
Core Labs' asset-light business model and emphasis on return on invested capital (ROIC) demonstrate a strategic approach to capital efficiency, which could be attractive to investors seeking companies with disciplined financial management in the cyclical oil and gas sector.
- SECOND QUARTER REVENUE OF
, UP SLIGHTLY SEQUENTIALLY AND YEAR-OVER-YEAR$130.6 MILLION - SECOND QUARTER OPERATING INCOME OF
; EX-ITEMS,$16.0 MILLION , UP$16.4 MILLION 10% SEQUENTIALLY AND5% YEAR-OVER-YEAR - SECOND QUARTER OPERATING MARGINS, EX-ITEMS, OF
13% - SECOND QUARTER GAAP EPS OF
; EX-ITEMS,$0.19 , UP$0.22 16% SEQUENTIALLY AND5% YEAR-OVER-YEAR - SECOND QUARTER FREE CASH FLOW OF
; NET DEBT REDUCED BY$14.3 MILLION $15.8 MILLION - COMPANY ANNOUNCES Q3 2024 QUARTERLY DIVIDEND
Core's CEO, Larry Bruno stated, "Core Lab revenue was up slightly sequentially, but our team delivered nice improvements in operating income, operating margins, incremental margins, free cash flow and earnings per share for the Company. Demand for our Reservoir Description services continued to grow across our international laboratory network despite continuing headwinds from on-going geopolitical conflicts. In Production Enhancement, revenue was down slightly sequentially, mostly related to lower international product sales, which offset the strong growth in the U.S. However, Production Enhancement margins expanded sequentially as savings from cost reductions and improvements in efficiencies were achieved. Personal face-to-face meetings with Middle Eastern operators during the second quarter reinforced continuing growth opportunities for both of Core's operating segments as an anticipated multi-year cycle of expanded client project activity unfolds across the region. Core's free cash flow improved significantly quarter-over-quarter and in addition to paying our quarterly dividend, we applied free cash to debt reduction. Core will continue to remain focused on executing its strategic business initiatives while also reducing our debt leverage ratio, which declined from 1.76 at the end of the first quarter to 1.66 at the end of the second quarter, the lowest level in over five years."
Reservoir Description
Reservoir Description operations are closely correlated with trends in international and offshore activity levels, with approximately
In the second quarter of 2024, Core Lab was engaged by an international operating company to determine the productive potential of recent natural gas discoveries offshore
Also in the second quarter of 2024, Core Laboratories' fluid specialists were commissioned by a Middle Eastern National Oil Company ("NOC") to conduct a coordinated, large-scale, surface sampling and laboratory analysis program to investigate emulsion problems. Water is a common byproduct of crude oil production and occurs as either "free" water, that readily settles in surface separators, or as dispersed droplets in the oil, known as an emulsion. Emulsions cause various reservoir, transportation, and processing facility-related challenges that require mitigation, usually in an Emulsion Treatment Plant ("ETP"). ETP's use techniques such as heating, chemical breakers and demulsifiers to disassociate the water from the oil. The problems with emulsions are compounded when multiple producing wells with varying water-cuts feed into a single production stream. This makes it difficult to identify the primary contributors to the emulsion-related issues. The NOC's wells in the area of concern are connected through transportation lines that feed into a central hub and, eventually, to an onshore processing facility. Core's analytical program identified the problematic wells and mixing locations, leading to the generation of a comprehensive risk map. These data are being used by the operator to evaluate the feasibility of isolating problematic wells and minimizing the impact on production while a longer-term mitigation strategy is developed.
Production Enhancement
Production Enhancement operations, which are focused on complex completions in unconventional oil and gas reservoirs in the
During the second quarter of 2024, an onshore
Also in the second quarter of 2024, a deepwater Gulf of
Liquidity, Free Cash Flow and Dividend
Core continues to focus on maximizing free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures. For the second quarter of 2024, cash from operations was approximately
Core expects the Company to continue generating positive free cash flow in future quarters. As of June 30, 2024, Core's net debt (defined as long term debt less cash and cash equivalents) was
On April 24, 2024, Core's Board of Directors ("Board") announced a quarterly cash dividend of
On July 24, 2024, the Board approved a cash dividend of
Return On Invested Capital
The Board and the Company's Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and FCF, factors that have high correlation to total shareholder return. Core's commitment to an asset-light business model and disciplined capital stewardship promotes capital efficiency and are designed to produce more predictable and superior long-term ROIC.
The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg, as the Company continues to believe superior ROIC will result in higher total shareholder return. Using Bloomberg's formula, the Company's ROIC as of June 30, 2024 was
Industry and Core Lab Outlook and Guidance
Core Lab maintains its constructive outlook on international upstream projects for 2024 and anticipates sustainable client activity growth in the years ahead to support rising crude-oil demand and energy security concerns. Aligned with this, Core will continue to execute its strategic plan of technology investments and pursue growth opportunities. IEA, EIA and OPEC projections continue to forecast growth in crude-oil demand of between one and two million barrels per day for both 2024 and 2025. The projected growth in crude-oil demand is in addition to the natural decline of production from existing fields. As such, continued investment in the development of onshore and offshore crude-oil fields will be required to meet the projected growth in demand. In the near-term, crude-oil markets will remain volatile due to global economic and geopolitical risks and uncertainties.
As international project activity continues to expand, committed long-term upstream projects from the
Reservoir Description's third quarter 2024 revenue is projected to range from
The Company's third quarter 2024 revenue is projected to range from
The Company's third quarter 2024 guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange. Third quarter 2024 guidance also assumes an effective tax rate of
Earnings Call Scheduled
The Company has scheduled a conference call to discuss Core's second quarter 2024 earnings announcement. The call will begin at 7:30 a.m. CDT / 8:30 a.m. EDT on Thursday, July 25, 2024. To listen to the call, please go to Core's website at www.corelab.com.
Core Laboratories Inc. is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance. The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements we make, includes forward-looking statements regarding the Company's future revenue, profitability, business strategies and developments, demand for the Company's products and services and for products and services of the oil and gas industry generally, made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business and general economic conditions, including inflationary pressures, the ability to achieve the benefits of the redomestication of the parent company from
The Company undertakes no obligation to publicly update or revise any forward-looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.
Visit the Company's website at www.corelab.com. Connect with Core Lab on Facebook, LinkedIn and YouTube.
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) | ||||||||||||||||
Three Months Ended | % Variance | |||||||||||||||
June 30, | March 31, | June 30, | vs. Q1-24 | vs. Q2-23 | ||||||||||||
REVENUE | $ | 130,577 | $ | 129,637 | $ | 127,881 | 0.7 % | 2.1 % | ||||||||
OPERATING EXPENSES: | ||||||||||||||||
Costs of services and product sales | 102,930 | 104,588 | 100,295 | (1.6) % | 2.6 % | |||||||||||
General and administrative expense | 10,259 | 11,789 | 5,811 | (13.0) % | 76.5 % | |||||||||||
Depreciation and amortization | 3,770 | 3,843 | 3,937 | (1.9) % | (4.2) % | |||||||||||
Other (income) expense, net | (2,390) | 846 | (1,068) | NM | NM | |||||||||||
Total operating expenses | 114,569 | 121,066 | 108,975 | (5.4) % | 5.1 % | |||||||||||
OPERATING INCOME | 16,008 | 8,571 | 18,906 | 86.8 % | (15.3) % | |||||||||||
Interest expense | 3,209 | 3,423 | 3,236 | (6.3) % | (0.8) % | |||||||||||
Income before income taxes | 12,799 | 5,148 | 15,670 | 148.6 % | (18.3) % | |||||||||||
Income tax expense (benefit) | 3,609 | 1,658 | (7,259) | 117.7 % | NM | |||||||||||
Net income | 9,190 | 3,490 | 22,929 | 163.3 % | (59.9) % | |||||||||||
Net income attributable to non-controlling interest | 158 | 270 | 83 | NM | NM | |||||||||||
Net income attributable to Core Laboratories Inc. | $ | 9,032 | $ | 3,220 | $ | 22,846 | 180.5 % | (60.5) % | ||||||||
Diluted earnings per share | $ | 0.19 | $ | 0.07 | $ | 0.48 | 171.4 % | (60.4) % | ||||||||
Diluted earnings per share attributable to Core Laboratories Inc. | $ | 0.19 | $ | 0.07 | $ | 0.48 | 171.4 % | (60.4) % | ||||||||
Diluted weighted average common shares outstanding | 47,743 | 47,703 | 47,497 | 0.1 % | 0.5 % | |||||||||||
Effective tax rate | 28 | % | 32 | % | (46) | % | NM | NM | ||||||||
SEGMENT INFORMATION: | ||||||||||||||||
Revenue: | ||||||||||||||||
Reservoir Description | $ | 86,277 | $ | 84,236 | $ | 83,384 | 2.4 % | 3.5 % | ||||||||
Production Enhancement | 44,300 | 45,401 | 44,497 | (2.4) % | (0.4) % | |||||||||||
Consolidated | $ | 130,577 | $ | 129,637 | $ | 127,881 | 0.7 % | 2.1 % | ||||||||
Operating income: | ||||||||||||||||
Reservoir Description | $ | 11,443 | $ | 6,892 | $ | 13,316 | 66.0 % | (14.1) % | ||||||||
Production Enhancement | 4,401 | 1,576 | 5,498 | 179.3 % | (20.0) % | |||||||||||
Corporate and Other | 164 | 103 | 92 | NM | NM | |||||||||||
Consolidated | $ | 16,008 | $ | 8,571 | $ | 18,906 | 86.8 % | (15.3) % | ||||||||
"NM" means not meaningful |
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) | ||||||
Six Months Ended June 30, | % Variance | |||||
2024 | 2023 | |||||
REVENUE | 1.6 % | |||||
OPERATING EXPENSES: | ||||||
Costs of services and product sales | 207,518 | 201,823 | 2.8 % | |||
General and administrative expense | 22,048 | 22,142 | (0.4) % | |||
Depreciation and amortization | 7,613 | 7,981 | (4.6) % | |||
Other (income) expense, net | (1,544) | (1,096) | NM | |||
Total operating expenses | 235,635 | 230,850 | 2.1 % | |||
OPERATING INCOME | 24,579 | 25,387 | (3.2) % | |||
Interest expense | 6,632 | 6,665 | (0.5) % | |||
Income before income taxes | 17,947 | 18,722 | (4.1) % | |||
Income tax expense (benefit) | 5,267 | (6,649) | NM | |||
Net income | 12,680 | 25,371 | (50.0) % | |||
Net income attributable to non-controlling interest | 428 | 152 | NM | |||
Net income attributable to Core Laboratories Inc. | (51.4) % | |||||
Diluted earnings per share | (50.9) % | |||||
Diluted earnings per share attributable to Core Laboratories Inc. | (50.9) % | |||||
Diluted weighted average common shares outstanding | 47,662 | 47,476 | 0.4 % | |||
Effective tax rate | 29 % | (36) % | NM | |||
SEGMENT INFORMATION: | ||||||
Revenue: | ||||||
Reservoir Description | 4.2 % | |||||
Production Enhancement | 89,701 | 92,665 | (3.2) % | |||
Total | 1.6 % | |||||
Operating income: | ||||||
Reservoir Description | 16.1 % | |||||
Production Enhancement | 5,977 | 8,779 | (31.9) % | |||
Corporate and Other | 266 | 821 | NM | |||
Total | (3.2) % | |||||
"NM" means not meaningful |
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) | ||||||||||||||||
% Variance | ||||||||||||||||
ASSETS: | June 30, | March 31, | December 31, | vs. Q1-24 | vs. Q4-23 | |||||||||||
Cash and cash equivalents | $ | 17,695 | $ | 14,913 | $ | 15,120 | 18.7 % | 17.0 % | ||||||||
Accounts receivable, net | 115,644 | 115,092 | 109,352 | 0.5 % | 5.8 % | |||||||||||
Inventories | 69,898 | 70,711 | 71,702 | (1.1) % | (2.5) % | |||||||||||
Other current assets | 30,291 | 28,331 | 26,962 | 6.9 % | 12.3 % | |||||||||||
Total current assets | 233,528 | 229,047 | 223,136 | 2.0 % | 4.7 % | |||||||||||
Property, plant and equipment, net | 98,510 | 98,521 | 99,626 | — % | (1.1) % | |||||||||||
Right of use assets | 55,689 | 53,636 | 53,842 | 3.8 % | 3.4 % | |||||||||||
Intangibles, goodwill and other long-term assets, net | 210,072 | 206,746 | 209,791 | 1.6 % | 0.1 % | |||||||||||
Total assets | $ | 597,799 | $ | 587,950 | $ | 586,395 | 1.7 % | 1.9 % | ||||||||
LIABILITIES AND EQUITY: | ||||||||||||||||
Accounts payable | $ | 36,863 | $ | 32,486 | $ | 33,506 | 13.5 % | 10.0 % | ||||||||
Short-term operating lease liabilities | 11,045 | 10,430 | 10,175 | 5.9 % | 8.6 % | |||||||||||
Other current liabilities | 49,690 | 42,552 | 44,416 | 16.8 % | 11.9 % | |||||||||||
Total current liabilities | 97,598 | 85,468 | 88,097 | 14.2 % | 10.8 % | |||||||||||
Long-term debt, net | 147,621 | 160,370 | 163,134 | (7.9) % | (9.5) % | |||||||||||
Long-term operating lease liabilities | 42,616 | 41,481 | 42,076 | 2.7 % | 1.3 % | |||||||||||
Other long-term liabilities | 64,270 | 63,214 | 63,281 | 1.7 % | 1.6 % | |||||||||||
Total equity | 245,694 | 237,417 | 229,807 | 3.5 % | 6.9 % | |||||||||||
Total liabilities and equity | $ | 597,799 | $ | 587,950 | $ | 586,395 | 1.7 % | 1.9 % |
CORE LABORATORIES INC. & SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | ||||||||
Six Months Ended June 30, | ||||||||
2024 | 2023 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
Net income | $ | 12,680 | $ | 25,371 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Stock-based compensation | 4,688 | 10,337 | ||||||
Depreciation and amortization | 7,613 | 7,981 | ||||||
Deferred income taxes | (777) | (10,949) | ||||||
Accounts receivable | (7,019) | (103) | ||||||
Inventories | 1,804 | (11,213) | ||||||
Accounts payable | 3,116 | (8,685) | ||||||
Other adjustments to net income | 571 | (7,167) | ||||||
Net cash provided by operating activities | 22,676 | 5,572 | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
Capital expenditures | (5,918) | (4,382) | ||||||
Net proceeds on life insurance policies and from insurance recovery | 2,776 | 3,375 | ||||||
Other investing activities | 798 | 189 | ||||||
Net cash used in investing activities | (2,344) | (818) | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
Repayment of long-term debt | (38,000) | (101,000) | ||||||
Proceeds from long-term debt | 22,000 | 111,000 | ||||||
Dividends paid | (938) | (934) | ||||||
Repurchase of common shares | (206) | (200) | ||||||
Equity related transaction costs | (594) | (2,553) | ||||||
Other financing activities | (19) | (291) | ||||||
Net cash provided by (used in) financing activities | (17,757) | 6,022 | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS | 2,575 | 10,776 | ||||||
CASH AND CASH EQUIVALENTS, beginning of period | 15,120 | 15,428 | ||||||
CASH AND CASH EQUIVALENTS, end of period | $ | 17,695 | $ | 26,204 |
Non-GAAP Information
Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items. For this reason, management uses certain non-GAAP measures that exclude these Items and believes that this presentation provides a clearer comparison with the results reported in prior periods. The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statements and filings with the Securities and Exchange Commission.
Reconciliation of Operating Income, Net Income and Diluted Earnings Per Share Attributable to Core Laboratories Inc. (In thousands, except per share data) (Unaudited) | ||||||||||||
Operating Income | ||||||||||||
Three Months Ended | ||||||||||||
June 30, | March 31, | June 30, | ||||||||||
GAAP reported | $ | 16,008 | $ | 8,571 | $ | 18,906 | ||||||
Stock compensation (1) | — | 3,458 | (934) | |||||||||
Loss on lease abandonment and assets write-down (2) | — | 1,809 | — | |||||||||
Severance costs | — | 824 | — | |||||||||
Gain on life insurance policies (3) | — | — | (1,965) | |||||||||
Foreign exchange losses (gains) | 388 | 285 | (386) | |||||||||
Excluding specific items | $ | 16,396 | $ | 14,947 | $ | 15,621 | ||||||
Net Income Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
June 30, | March 31, | June 30, | ||||||||||
GAAP reported | $ | 9,032 | $ | 3,220 | $ | 22,846 | ||||||
Stock compensation (1) | — | 2,766 | (747) | |||||||||
Loss on lease abandonment and assets write-down (2) | — | 1,447 | — | |||||||||
Severance costs | — | 659 | — | |||||||||
Gain on life insurance policies (3) | — | — | (1,572) | |||||||||
Foreign exchange losses (gains) | 310 | 229 | (309) | |||||||||
Reversal of net deferred tax liabilities and/or effect of higher (lower) tax rate (4) | 1,050 | 628 | (10,394) | |||||||||
Excluding specific items | $ | 10,392 | $ | 8,949 | $ | 9,824 | ||||||
Diluted Earnings Per Share Attributable to Core Laboratories Inc. | ||||||||||||
Three Months Ended | ||||||||||||
June 30, | March 31, | June 30, | ||||||||||
GAAP reported | $ | 0.19 | $ | 0.07 | $ | 0.48 | ||||||
Stock compensation (1) | — | 0.06 | (0.02) | |||||||||
Loss on lease abandonment and assets write-down (2) | — | 0.03 | — | |||||||||
Severance costs | — | 0.01 | — | |||||||||
Gain on life insurance policies (3) | — | — | (0.03) | |||||||||
Foreign exchange losses (gains) | 0.01 | 0.01 | — | |||||||||
Reversal of net deferred tax liabilities and/or effect of higher (lower) tax rate (4) | 0.02 | 0.01 | (0.22) | |||||||||
Excluding specific items | $ | 0.22 | $ | 0.19 | $ | 0.21 | ||||||
(1) Three months ended March 31, 2024 includes the acceleration of stock compensation expense associated with employees reaching eligible retirement age. Three months ended June 30, 2023 include reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share awards recorded in G&A expenses. | ||||||||||||
(2) Three months ended March 31, 2024 include the write-down of leasehold improvements, right of use assets and/or other assets and exit costs associated with consolidation of certain facilities. | ||||||||||||
(3) Three months ended June 30, 2023 includes gain on life insurance policies death benefit proceeds recorded in G&A expenses. | ||||||||||||
(4) Three months ended June 30, 2024 and March 31, 2024 includes the effect to reflect tax expense at a normalized rate of |
Segment Information (In thousands) (Unaudited) | ||||||||||||
Operating Income | ||||||||||||
Three Months Ended June 30, 2024 | ||||||||||||
Reservoir Description | Production Enhancement | Corporate and Other | ||||||||||
GAAP reported | $ | 11,443 | $ | 4,401 | $ | 164 | ||||||
Foreign exchange losses (gains) | 346 | 114 | (72) | |||||||||
Excluding specific items | $ | 11,789 | $ | 4,515 | $ | 92 |
Return on Invested Capital
Return on Invested Capital ("ROIC") is presented based on management's belief that this non-GAAP measure is useful information to investors and management when comparing profitability and the efficiency with which capital has been employed over time relative to other companies. The Board has established an internal metric to demonstrate ROIC performance relative to the oilfield service companies listed as Core's Comp Group by Bloomberg. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.
ROIC of
Free Cash Flow
Core uses the non-GAAP financial measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is an important measurement because it represents the cash from operations, in excess of capital expenditures, available to operate the business and fund non-discretionary obligations. Free cash flow is not a measure of operating performance under GAAP and should not be considered in isolation nor construed as an alternative consideration to operating income, net income, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP. Free cash flow should not be considered a measure of liquidity. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.
Computation of Free Cash Flow (In thousands) (Unaudited) | |||||||||
Three Months Ended | Six Months Ended | ||||||||
June 30, 2024 | June 30, 2024 | ||||||||
Net cash provided by operating activities | $ | 17,146 | $ | 22,676 | |||||
Capital expenditures | (2,866) | (5,918) | |||||||
Free cash flow | $ | 14,280 | $ | 16,758 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/core-lab-reports-second-quarter-2024-results-302205824.html
SOURCE Core Laboratories Inc
FAQ
What was Core Laboratories' (CLB) revenue for Q2 2024?
How much did Core Laboratories (CLB) reduce its net debt in Q2 2024?
What was Core Laboratories' (CLB) EPS for Q2 2024?
How much free cash flow did Core Laboratories (CLB) generate in Q2 2024?